A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
ACADEMIA
Japan Consortium to Promote Domestic R&D of Cannabis-Derived Meds
The use of cannabis-derived medicines is now allowed in Japan through the amendment of the Cannabis Control Act and the Narcotics and Psychotropics Control Act late last year, but domestic R&D in the arena is still in its infancy. To…
To read the full story
Related Article
- Hemp Cannabinoid Consortium Draws 40 Inquiries from Industry and Academia
August 22, 2025
- Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
- Japan Grants Orphan Tag to Cannabidiol, 6 More APIs
June 10, 2024
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
ACADEMIA
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
- Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
September 3, 2025
- Tohoku University Trial Finds Kidney Benefits for Constipation Drug Lubiprostone
September 3, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…